Pardes Biosciences is a clinical-stage biopharmaceutical company that uses reversible-covalent chemistry to discover and develop novel oral drug candidates. Their lead product candidate, PBI-0451, is an oral antiviral drug being developed to treat and prevent SARS-CoV-2 infections. The company is reimagining the patient journey to access these medicines by capitalizing on emerging patient-friendly innovations such as telehealth and at-home diagnostic tools. Pardes Biosciences is on a mission to stop the pandemic and start a movement to help patients get well sooner.